Rutgers University utilizes Virtuix's Omni One platform for research on AI-assisted neurodivergent therapy and immersive behavioral analytics.
Quiver AI Summary
Virtuix Holdings Inc. announced that Rutgers University has implemented its Omni One omni-directional treadmill for research into AI-assisted therapies focused on neurodivergent conditions, particularly autism in children. This collaboration aims to investigate the potential of combining immersive virtual environments with full-body movement and AI interactions to improve therapeutic outcomes compared to traditional methods. Researchers will assess various patient engagement and movement metrics over time, highlighting the opportunity for movement-centered, AI-enhanced virtual reality solutions in healthcare and rehabilitation. This initiative not only reflects Virtuix's innovative approach but also represents a validation of its technology in advanced therapeutic research settings, with similar applications being explored at Florida Gulf Coast University.
Potential Positives
- Collaboration with Rutgers University validates Virtuix's immersive XR platform within advanced healthcare and therapeutic research environments.
- Initiative to explore AI-assisted neurodivergent therapy opens potential new therapeutic applications for the company's technology, broadening its market reach.
- Projected growth of the autism spectrum disorder treatment market may increase demand for Virtuix’s innovative therapy solutions, positioning the company for future growth.
- Deployment at multiple academic institutions highlights the versatility and applicability of the Omni One platform beyond traditional consumer and defense markets.
Potential Negatives
- Partnerships with educational institutions like Rutgers may highlight a dependency on external collaborations for innovation, suggesting potential limitations in internal R&D capabilities.
- The focus on emerging applications in therapy may indicate that the company is diversifying due to stagnation or saturation in their traditional consumer and defense markets.
- Forward-looking statements in the press release reveal uncertainty regarding future performance and potential risks, which could impact investor confidence.
FAQ
What is the Omni One platform?
The Omni One is an omni-directional treadmill designed for immersive virtual reality experiences and research applications.
How will Omni One assist in neurodivergent therapy?
Omni One aims to enhance engagement in therapeutic settings through movement-centered interactions and AI-enhanced immersive environments.
Which institution is collaborating with Virtuix for this initiative?
Virtuix is collaborating with Rutgers University for research on AI-assisted behavioral therapy applications.
What therapeutic conditions will the research focus on?
The research will primarily focus on autism therapy for children and other neurodevelopmental therapies.
What growth is projected for autism treatment technologies?
The autism treatment market is expected to grow from $9.2 billion in 2026 to over $18 billion by 2034.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$VTIX Insider Trading Activity
$VTIX insiders have traded $VTIX stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $VTIX stock by insiders over the last 6 months:
- JAN ROGER GOETGELUK (Chief Executive Officer) has made 0 purchases and 18 sales selling 479,721 shares for an estimated $2,521,394.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$VTIX Hedge Fund Activity
We have seen 19 institutional investors add shares of $VTIX stock to their portfolio, and 0 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 307,519 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,081,903
- GEODE CAPITAL MANAGEMENT, LLC added 247,841 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,677,883
- MILLENNIUM MANAGEMENT LLC added 238,915 shares (+inf%) to their portfolio in Q1 2026, for an estimated $1,617,454
- BANK OF AMERICA CORP /DE/ added 52,277 shares (+inf%) to their portfolio in Q1 2026, for an estimated $353,915
- INSIGHT WEALTH PARTNERS, LLC added 48,298 shares (+inf%) to their portfolio in Q1 2026, for an estimated $326,977
- GOLDMAN SACHS GROUP INC added 46,441 shares (+inf%) to their portfolio in Q1 2026, for an estimated $314,405
- NORTHERN TRUST CORP added 45,690 shares (+inf%) to their portfolio in Q1 2026, for an estimated $309,321
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Full Release
Rutgers University Deploys Omni One Platform to Explore Movement-Centered XR and AI-Enhanced Behavioral Therapy Applications
Collaboration Broadens Virtuix’s Applications Beyond Traditional Consumer and Defense End Markets
AUSTIN, Texas, May 20, 2026 (GLOBE NEWSWIRE) -- Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of immersive full-body virtual reality systems, today announced that Rutgers University has deployed the Omni One omni-directional treadmill platform at WINLAB for research and development focused on AI-assisted neurodivergent therapy and immersive behavioral analytics applications, including autism therapy for children.
The initiative will explore how immersive virtual environments, combined with full-body movement on Omni One and adaptive AI interaction, may enhance engagement and learning outcomes in therapeutic settings beyond traditional approaches that rely primarily on visual and audio interaction.
The collaboration combines Virtuix’s locomotion platform with AI-enhanced immersive environments designed to support movement-centered interactions and spatial navigation. Researchers plan to evaluate patients’ attention, movement patterns, response timing, engagement consistency, and spatial interaction over time.
“We believe movement-centered, AI-enabled virtual reality represents a significant emerging opportunity across therapy, rehabilitation, and other healthcare applications,” said Jan Goetgeluk, Chief Executive Officer of Virtuix. “By introducing full-body movement and AI interaction through Omni One, we are enabling entirely new categories of user engagement beyond traditional VR experiences. We are excited to work with Rutgers University to explore these possibilities.”
“This collaboration allows us to explore how VR immersion combined with full-body locomotion and AI may create new approaches for neurodevelopmental therapy,” said Dr. Yingying Chen, Department Chair and Distinguished Professor of Electrical and Computer Engineering at Rutgers University. “We believe movement-centered immersive systems can open important new directions for engagement within therapeutic environments.”
The Rutgers collaboration represents an important validation of Virtuix’s immersive XR platform within advanced university-led healthcare and therapeutic research environments. The initiative follows a recent Omni One deployment to Florida Gulf Coast University for evaluation in rehabilitation and clinical simulation applications. While Virtuix’s primary focus remains on consumer entertainment and defense applications, the company believes full-body movement within AI-enabled environments may play an increasingly important role across next-generation healthcare and therapeutic applications.
According to Fortune Business Insights, the global autism spectrum disorder (ASD) treatment market is projected to expand from approximately $9.2 billion in 2026 to more than $18 billion by 2034, growing at a compound annual growth rate of 9%. The projected growth underscores the increasing demand for new therapeutic solutions, including technology enabled engagement platforms and AI-assisted behavioral analytics.
About Virtuix
Virtuix Inc. (NASDAQ: VTIX) is a leading manufacturer of full-body virtual reality systems for consumer, enterprise, healthcare, and defense markets. The company’s premier portfolio of “Omni” omni-directional treadmills enables users to walk and run in 360 degrees inside video games and other immersive virtual reality applications. With a commitment to innovation, Virtuix continues to push the boundaries of XR, spatial computing, and AI-driven immersive experiences. For more information, visit virtuix.com .
Please visit the Company’s new Investor Relations website at invest.virtuix.com .
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding the Company’s plans to pursue strategic acquisitions, the potential benefits of any such acquisition, the expected synergies, the potential impact on revenues or shareholder value, and the Company’s position in the defense training market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business; risks related to government contracting, including contract cancellations, modifications, or funding changes; the uncertainties related to market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement filed with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Visit Us on Social Media:
LinkedIn
Instagram
Facebook
YouTube
TikTok
X
Company Contact
Lauren Premo
Virtuix Inc.
[email protected]
Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
[email protected]